Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
The present invention provides methods for treating and preventing benign breast disease by administering 4-hydroxy tamoxifen to a patient. When percutaneously administered to a patient's breasts, 4-hydroxy tamoxifen concentrates locally, and exerts an anti-estrogenic effect. In patients with benign breast disease, this effect induces disease regression. In patients at risk for developing breast cancer, the anti-estrogenic effect prevents formation of benign breast conditions that can lead to cancer.
1. A method of treating benign breast disease in a female patient, comprising percutaneously administering 4-hydroxy tamoxifen to a female patient having benign breast disease, wherein said 4-hydroxy tamoxifen is administered in a vehicle containing isopropyl myristate as a penetration enhancer.
2. A method according to claim 1 , wherein about 0.25 to 2.0 mg/breast of said 4-hydroxy tamoxifen is administered to said patient per day.
3. A method according to claim 1 , wherein said 4-hydroxy tamoxifen is formulated in a hydroalcoholic gel, a hydroalcoholic solution, a patch, an ointment, a cream, an emulsion (lotion), a powder or an oil.
4. A method according to claim 3 , wherein said 4-hydroxy tamoxifen is formulated in a hydroalcoholic gel.
5. A method according to claim 3 , wherein said 4-hydroxy tamoxifen is formulated in a hydroalcoholic composition containing a penetration enhancer, an aqueous vehicle, an alcoholic vehicle and a gelling agent.
6. A method according to claim 5 , wherein said hydroalcoholic composition comprises a neutralizing agent.
7. A method according to claim 5 , wherein said hydroalcoholic composition comprises:
a) about 0.01% to 0.20% by weight of 4-hydroxy tamoxifen,
b) about 0.5% to 2% by weight of isopropyl myristate,
c) about 60% to 75% by weight of absolute alcohol,
d) about 25% to 40% by weight of aqueous vehicle,
e) about 0.5% to 5% by weight of gelling agent,
wherein the percentage of components are weight to weight of the composition.
8. A method according to claim 7 , wherein said alcohol is ethanol or isopropanol, and constitutes in absolute form about 60% to 75% by weight of the composition.
9. A method according to claim 7 , wherein said aqueous vehicle is a phosphate buffered solution, and constitutes about 25% to 40% by weight of the composition.
10. A method according to claim 7 , wherein said gelling agent is a polyacrylic acid or hydroxypropylcellulose, and constitutes about 0.5% to 5% by weight of the composition.
11. A method according to claim 7 , wherein said hydroalcoholic composition further comprises a neutralizing agent selected in the group consisting of sodium hydroxide, ammonium hydroxide, potassium hydroxide, arginine, aminomethylpropanol, trolamine and tromethamine, which neutralizing agent exists at a neutralizing agent/gelling agent ratio between about 4:1 and 1:1.
12. A method according to claim 7 , wherein said hydroalcoholic composition is packaged in a unit dose packet or in a multiple dose container with a metered pump.
13. A method according to claim 1 , wherein said benign breast disease is a proliferative breast disease.
14. A method according to claim 13 , wherein said proliferative breast disease is selected from the group consisting of adenosis, cysts, duct ectasia, fibroadenoma, fibrocystic disease, fibrosis, hyperplasia and metaplasia.
15. A method according to claim 14 , wherein said patient is pre-menopausal.
16. A method according to claim 1 , wherein said benign breast disease has an estrogen-related component.